European Court Upholds €60M Fine on Teva and Cephalon for Generic Drug Delay

Pieter Gunst01 mins

An appeal by Teva and its subsidiary Cephalon was dismissed by a European court on Wednesday, which targeted to invalidate a fine totalling over €60 million ($63.2 million). The fine was initially imposed for their alleged conspiracy back in 2005, with an intended aim to prevent the entry of a generic version of the sleep disorder drug, Provigil, into the market. Further details of the case can be discovered on Law360.